TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: quality-adjusted life-years (QALY)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: erythrocyte morphodensitometric parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: hemostatic characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: blood gas transport characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Maxillary forward displacement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in ANS-Me distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mandibular effective length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absence of subretinal fluid at the macula
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean logMAR BCVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean OCT CFT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance in pre‐anaesthetic setup and evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: length gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: self-reported being smoke-free at three months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bioverified as smoke-free
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health-related quality of life (HQL) improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: aerobic capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: postoperative drainage volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: FDG uptake in muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severe liver fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean Unified Parkinson's Disease Rating Scale motor part score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in HDL-C
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in triglycerides
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in serum creatinine
Endpoint domain: Adverse events/effects
Primary endpoint: Antiparkinsonian response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dyskinesias
Endpoint domain: Adverse events/effects
Primary endpoint: Hunger scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvements in cardiovascular risk factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Health-related quality of life (HRQL) of the child
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: lung V5
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: maximum cord dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: number of moderate to severe depressive days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of death/MI at 30 days
Endpoint domain: Mortality/survival
Primary endpoint: Median area under the curve of decreased total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical response to neoadjuvant chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: change in quality of food brought to school
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intrahepatic fat reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Liver function markers improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: modified Rankin score of 2 or less
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum DHEA-S concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Proportion of repeated attempts to harm themselves
Endpoint domain: Adverse events/effects
Primary endpoint: perioperative plasma aminotransferase level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Predictors of massive transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total mortality at 30 days
Endpoint domain: Mortality/survival
Primary endpoint: rate of moderate/severe hemorrhage
Endpoint domain: Adverse events/effects
Primary endpoint: tolerability and enjoyment of exercise
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: six-year prolonged abstinence
Endpoint domain: Mortality/survival
Primary endpoint: reduction in number of days smoked in the past month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increase in the length of the longest quit attempt in the past year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to denitrogenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of thromboembolism
Endpoint domain: Mortality/survival
Primary endpoint: Unsuccessful attempts of venepuncture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ventricular rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate-pressure products
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Role emotional
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time to worsening of symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: mean time to reepithelialization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: median erythema score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: intolerance of the molecule
Endpoint domain: Adverse events/effects
Primary endpoint: prolongation of pregnancy more than 48 hours
Endpoint domain: Physiological/clinical
Primary endpoint: mean reductions in HIV-1 RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relapses of chronic UC
Endpoint domain: Mortality/survival
Primary endpoint: Mean serum chromium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean high-density lipoprotein-cholesterol level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean triglycerides levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: infection in mothers and neonates
Endpoint domain: Adverse events/effects
Primary endpoint: proportion reporting any drug use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: drug use frequency on a five-point scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total days of drug use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ILC flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Serum bactericidal antibody (SBA) titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-PRP antibody concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: ACR response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: empowerment scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: internet games addiction scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Serum creatinine and urea nitrogen concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Reduction in major cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: overall gross motor development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: locomotion test scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rehospitalisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days in hospital
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in proteinuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: change from baseline in primary endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30-day all-cause hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: 30-day cardiovascular hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: 30-day heart failure hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: erythropoietic response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of detecting focal cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: OHCA survival outcomes
Endpoint domain: Mortality/survival
Primary endpoint: Event-Free Survival (EFS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: malnutrition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: urinary incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Serum apo-B levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Eruption space differences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative vaginal cuff infections
Endpoint domain: Adverse events/effects
Primary endpoint: Urinary infections
Endpoint domain: Adverse events/effects
Primary endpoint: Reduced percentage of leukemia blasts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Heart rate recovery 1 minute after exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: anti-smoking attitudes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: perceived control over smoking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: UPDRS part II ADL measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lost to follow-up (LTFU) incidence
Endpoint domain: Mortality/survival
Primary endpoint: Change in health status (SF-36)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement in EDVR function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Decrease in low-density lipoprotein cholesterol (LDL-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Restoration of night vision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total bloody drainage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: immediate wound problem
Endpoint domain: Adverse events/effects
Primary endpoint: Limb pain score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coping skills
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: percentage of correct identifications of target stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: percentage of commission errors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: discriminability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: IVH volume reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone sclerostin mRNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SOSTDC1 mRNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in inflammatory genes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adult height (AH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total scores of PANSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Maximum weight‐bearing on the affected leg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IL-18 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Complete resolution of heartburn
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: comfort score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: maximum VAS score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: percent of sleep time
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: number of waking bouts
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Informed decision-making
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Transferrin saturation percentage (TS%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of gastrointestinal toxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Esophagitis scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: CD4(+):CD8(+) ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: marginal adaptation scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: marginal staining scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: surface roughness scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: H‐B facial nerve function grading
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Average duration of effective treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with follow-up PCP visits
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Implementation of pulmonary rehabilitation programme
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: HA seropositivity rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 10-year disease-free survival rates
Endpoint domain: Mortality/survival
Primary endpoint: 10-year overall survival rates
Endpoint domain: Mortality/survival
Primary endpoint: Freedom from myocardial infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Disease Activity Score 28 (DAS 28 score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of tender joints
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Persistent reduction in pain measured by TPC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical function measured by 6MWT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grip Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: measures of hostility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: red-marrow absorbed dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: remnant cumulated activity per unit administered activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ultrasonographic distance of the joint capsule from the bone rim
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rates in patients with normalized EEG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Co-enrollment rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Clinical cure of VVC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mycological cure of VVC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: post-move walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RGS (Response Grading Scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvements in lid papillae
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency and intensity of symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: mean CLDEQ‐8 scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: consistency in tongue carcinoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in the height of keloids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recognition of Brugada
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Recognition of long QT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Recognition of heart block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: TNSS reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: neurocognitive disadvantage
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Reduction in 2-hour glucose level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cmax and AUC0‐∞ values for eperisone and aceclofenac
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PGEI requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical safety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: imaging quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MODI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of caregiving
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: improved intermediate vision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improved near vision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: better contrast sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: claim duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: pain severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: functional status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Force regulation of the circumoral region
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decreased production of reactive oxygen species
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: decreased leukocyte activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: calcium mobilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of echo types I + II
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: modified Harris hip score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post defecation pain severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rectal tenesmus severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence rate of hemorrhoids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived Stress scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patient Activation Measure score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: NIH PROMIS Global Mental Health score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: NIH PROMIS Global Physical Health score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mouth opening capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: N400 response to abnormal speech
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: % predicted PEF at 60 min
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes